Clinical Trials on Polychondritis, Relapsing

Total 764 results

Hasselt University

Recruiting

Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Belgium
Bristol-Myers Squibb

Recruiting

A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (SWITCH - ITA)

Multiple Sclerosis, Relapsing-Remitting

Italy
Amsterdam UMC, location VUmc

Recruiting

B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis (BLOOMS)

Multiple Sclerosis, Relapsing-Remitting

Netherlands
Immunic AG

Recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (ENSURE-2)

Multiple Sclerosis, Relapsing-Remitting

Turkey, United States, India, United Kingdom, Bosnia and Herzegovina, Estonia, Poland, Romania, Serbia, Ukraine, Armenia, Peru
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

Relapsing Multiple Sclerosis

United States, Canada, China, Spain, Italy, France, Slovenia, Japan, Turkey, Argentina, Estonia, Greece, Mexico, Poland, Sweden, Croatia, South Africa, Brazil, Slovakia, Bulgaria, Romania, India, Portugal, United Kingdom, Puerto Rico
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

Relapsing Multiple Sclerosis

China, Spain, Switzerland, Taiwan, United States, Italy, Austria, Belgium, Saudi Arabia, United Arab Emirates, Latvia, Poland, Argentina, India, Croatia, Bulgaria, Malaysia, Slovakia, Israel, Lebanon, Guatemala, Netherlands, Colombia, Chil... and more
University of Alabama at Birmingham

Recruiting

Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Berkovich, Regina MD, PhD Inc.
Biogen; Cedars-Sinai Medical Center

Recruiting

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Riley Bove, MD

Recruiting

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis (ReWRAP)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Asuman Kucukoner

Completed

Speech in Noise Discrimination Skills in Multiple Sclerosis Patients.

Multiple Sclerosis-Relapsing-Remitting

Turkey
Biogen

Terminated

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

Germany
Hoffmann-La Roche

Completed

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Canada, United States
Rennes University Hospital

Active, not recruiting

Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis (MS-TRACTS)

Multiple Sclerosis, Relapsing-Remitting

France
Celgene

Completed

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Germany
Biogen

Completed

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Multiple Sclerosis, Relapsing-Remitting

United States, Spain, Canada, Australia, Germany, Italy, United Kingdom, Belgium, Netherlands, France, Israel
Mapi Pharma Ltd.

Completed

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Multiple Sclerosis, Relapsing-Remitting

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Estonia, Georgia, Israel, Moldova, Republic of, Russian Federation, Ukraine
Uppsala University
Karolinska University Hospital; Sahlgrenska University Hospital, Sweden; University... and other collaborators

Completed

Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden (AutoMS-Swe)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

Sweden
Biogen

Completed

Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP (TEC-ADHERE)

Multiple Sclerosis, Relapsing-Remitting

France
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Multiple Sclerosis, Relapsing-Remitting

Belgium, United Kingdom, Australia, Netherlands, Ireland, Norway, Turkey, Estonia, Denmark, Germany, Italy, Spain, Switzerland, France, Finland, Sweden, Czechia
TG Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) (ULTIMATE 1)

Relapsing Multiple Sclerosis (RMS)

United States
University of California, San Francisco

Completed

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis (ReBUILD)

Multiple Sclerosis, Relapsing-Remitting

United States
Anders Svenningsson

Completed

RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. (RIFUND-MS)

Multiple Sclerosis, Relapsing-Remitting

Sweden
Biocad

Completed

Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Russian Federation
Karolinska Institutet

Active, not recruiting

RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS (RIDOSE-MS)

Multiple Sclerosis, Relapsing-Remitting

Sweden
Lama Saad El-Din Mahmoud

Completed

Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis (core stability)

Multiple Sclerosis, Relapsing-Remitting

Egypt
University of Illinois at Urbana-Champaign

Unknown

Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
National Institute of Neurological Disorders and...

Terminated

Oral Guanabenz for Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Mallinckrodt
Mallinckrodt ARD Inc.

Completed

Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse

Multiple Sclerosis, Relapsing-Remitting

United States
National Institute of Neurological Disorders and...

Completed

Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
University of Illinois at Chicago
Takeda Pharmaceuticals North America, Inc.

Completed

Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Completed

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Bulgaria, Belgium, Poland, Lithuania, Kuwait, Turkey
Dr. med. Micha Loebermann

Completed

Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Germany
MedImmune LLC

Completed

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing Forms

United States, Spain, Poland, Ukraine
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. (P1A114919)

Multiple Sclerosis, Relapsing-Remitting

Australia
National Institute of Neurological Disorders and...

Completed

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
GlaxoSmithKline

Terminated

A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

United Kingdom
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN); Repligen Corporation

Completed

Safety of RG2077 in Patients With Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United Kingdom, United States, Canada, Belgium, Czech Republic, France, Germany, Netherlands
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

Completed

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Multiple Sclerosis, Relapsing-Remitting

United States, Canada
GlaxoSmithKline

Completed

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Spain, Bulgaria, Ukraine, United Kingdom, Sweden, Germany, Canada, Czech Republic
Universidad Austral de Chile
University of Chile; Comisión Nacional de Investigación Científica y Tecnológica

Completed

Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS) (PCNS-EM)

Multiple Sclerosis, Relapsing-Remitting

Chile
Grifols Therapeutics LLC

Completed

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis (PRIVIG)

Multiple Sclerosis, Relapsing-Remitting

Canada, Israel, United States, Austria, Czech Republic, Germany, Greece, Hungary, Poland, Slovakia, Sweden, United Kingdom
Tehran University of Medical Sciences

Completed

Melatonin in Relapsing-Remitting Multiple Sclerosis Patients

Multiple Sclerosis, Relapsing-Remitting

Iran, Islamic Republic of
Bayer

Completed

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose (Beyond)

Multiple Sclerosis, Relapsing-Remitting

Belgium, Israel, United States, Canada, France, Switzerland, Ireland, Italy, Australia, Spain, Austria, Germany, Brazil, Netherlands, Poland, Russian Federation, Hungary, Slovenia, Argentina, Ukraine, Greece, Sweden, Finland, Latvia, No... and more
Genzyme, a Sanofi Company
Bayer

Completed

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States, Russian Federation, Poland, Croatia, United Kingdom
Genzyme, a Sanofi Company
Bayer

Completed

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One (CARE-MS I)

Multiple Sclerosis, Relapsing-Remitting

Australia, France, United States, Germany, Canada, United Kingdom, Russian Federation, Argentina, Brazil, Croatia, Poland, Serbia, Sweden, Ukraine, Czech Republic, Mexico
Merck KGaA, Darmstadt, Germany

Completed

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting
Bayer

Completed

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Merck KGaA, Darmstadt, Germany
Merck spol.s.r.o., Czech Republic

Completed

Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® (SKORE)

Multiple Sclerosis, Relapsing-Remitting

Czech Republic
Bayer

Completed

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis (ROBUST)

Multiple Sclerosis, Relapsing-Remitting

United States

Clinical Trials on Polychondritis, Relapsing

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations